A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 18 May 2017 Planned number of patients changed from 2000 to 1637.
- 18 May 2017 Planned End Date changed from 1 Nov 2022 to 1 May 2024.
- 18 May 2017 Planned primary completion date changed from 1 Nov 2022 to 1 May 2024.